Kosuke Ichikawa
Impact in
- Oncology top 10%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
Papers in
- Oncology 11
- Cancer Immunotherapy and Biomarkers 6
- CAR-T cell therapy research 3
- Lung Cancer Research Studies 2
-
- Lung Cancer Treatments and Mutations 5
- Co-authors
- Satoshi Watanabe (13 shared papers)Hirohisa Yoshizawa (10 shared papers)Junta Tanaka (5 shared papers)Takao Miyabayashi (9 shared papers)Rie Kondo (9 shared papers)Jun Koshio (7 shared papers)Ichiei Narita (5 shared papers)Hiroshi Kagamu (6 shared papers)
- Journals
- Translational Lung Cancer Research (3 papers)The Journal of Immunology (1 paper)Blood (1 paper)Cancer Medicine (1 paper)Japanese Journal of Clinical Oncology (1 paper)
- Partner nations
- JapanUnited States
In The Last Decade
Kosuke Ichikawa
16 papers receiving 546 citations
Kosuke Ichikawa's Hit Papers
Peers
Comparison fields: 5 of 82
- Oncology 241
- Cancer Research 71
- Pulmonary and Respiratory Medicine 123
- Immunology 69
- Molecular Biology 150
Countries citing papers authored by Kosuke Ichikawa
This map shows the geographic impact of Kosuke Ichikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kosuke Ichikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kosuke Ichikawa more than expected).
Fields of papers citing papers by Kosuke Ichikawa
This network shows the impact of papers produced by Kosuke Ichikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kosuke Ichikawa. The network helps show where Kosuke Ichikawa may publish in the future.
Co-authors
The 25 scholars most cited alongside Kosuke Ichikawa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis Hit paper breakdown → | 2011 | 337 |
| 2 | 2012 | 58 | |
| 3 | 2018 | 38 | |
| 4 | 2015 | 20 | |
| 5 | 2020 | 16 | |
| 6 | 2019 | 13 | |
| 7 | 2011 | 12 | |
| 8 | 2022 | 11 | |
| 9 | 2019 | 10 | |
| 10 | 2020 | 9 | |
| 11 | 2022 | 7 | |
| 12 | 2012 | 6 | |
| 13 | 2021 | 6 | |
| 14 | 2022 | 5 | |
| 15 | 2019 | 4 | |
| 16 | 2015 | 3 | |
| 17 | 2025 | 0 | |
| 18 | 2026 | 0 | |
| 19 | 2015 | 0 |
About Kosuke Ichikawa
Kosuke Ichikawa is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Immunology, Pathology and Forensic Medicine and Radiation, having authored 19 papers that have together received 555 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (5 papers), CAR-T cell therapy research (3 papers), Lung Cancer Research Studies (2 papers), Immunotherapy and Immune Responses (2 papers), T-cell and B-cell Immunology (2 papers), Immune Cell Function and Interaction (2 papers) and Cancer Genomics and Diagnostics (1 paper). The work is most often cited by research in Oncology (241 citations), Cancer Research (71 citations), Pulmonary and Respiratory Medicine (123 citations), Immunology (69 citations) and Molecular Biology (150 citations). Kosuke Ichikawa has collaborated with scholars based in Japan and United States. Frequent co-authors include Satoshi Watanabe, Hirohisa Yoshizawa, Junta Tanaka, Takao Miyabayashi, Rie Kondo, Jun Koshio, Ichiei Narita, Hiroshi Kagamu, Hiroshi Tanaka and Junko Baba. Their work appears in journals such as Translational Lung Cancer Research, The Journal of Immunology, Blood, Cancer Medicine and Japanese Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.